 Melanoma
"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Descriptor ID |
D008545
|
| MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
| Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in this website by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 10 | 7 | 17 | | 1991 | 13 | 2 | 15 | | 1992 | 9 | 2 | 11 | | 1993 | 19 | 6 | 25 | | 1994 | 25 | 4 | 29 | | 1995 | 27 | 12 | 39 | | 1996 | 41 | 5 | 46 | | 1997 | 37 | 4 | 41 | | 1998 | 50 | 8 | 58 | | 1999 | 44 | 5 | 49 | | 2000 | 37 | 6 | 43 | | 2001 | 48 | 4 | 52 | | 2002 | 61 | 9 | 70 | | 2003 | 65 | 10 | 75 | | 2004 | 65 | 9 | 74 | | 2005 | 51 | 10 | 61 | | 2006 | 82 | 6 | 88 | | 2007 | 56 | 6 | 62 | | 2008 | 88 | 13 | 101 | | 2009 | 79 | 10 | 89 | | 2010 | 103 | 12 | 115 | | 2011 | 116 | 10 | 126 | | 2012 | 115 | 17 | 132 | | 2013 | 102 | 25 | 127 | | 2014 | 99 | 13 | 112 | | 2015 | 92 | 6 | 98 | | 2016 | 98 | 5 | 103 | | 2017 | 125 | 9 | 134 | | 2018 | 109 | 15 | 124 | | 2019 | 55 | 1 | 56 | | 2020 | 7 | 2 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Galvani E, Mundra PA, Valpione S, Garcia-Martinez P, Smith M, Greenall J, Thakur R, Helmink B, Andrews MC, Boon L, Chester C, Gremel G, Hogan K, Mandal A, Zeng K, Banyard A, Ashton G, Cook M, Lorigan P, Wargo JA, Dhomen N, Marais R. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nat Commun. 2020 02 12; 11(1):853.
-
Hanks JE, Kovatch KJ, Ali SA, Roberts E, Durham AB, Smith JD, Bradford CR, Malloy KM, Boonstra PS, Lao CD, McLean SA. Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety. Otolaryngol Head Neck Surg. 2020 04; 162(4):520-529.
-
Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, Chalasani N. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. Am J Gastroenterol. 2020 02; 115(2):251-261.
-
Bhargava P, Flynt L, Marcal L. Nivolumab-Induced Subcutaneous Fat Necrosis: Another FDG-Avid Immune-Related Adverse Event. Clin Nucl Med. 2020 Feb; 45(2):125-126.
-
Parisi G, Saco JD, Salazar FB, Tsoi J, Krystofinski P, Puig-Saus C, Zhang R, Zhou J, Cheung-Lau GC, Garcia AJ, Grasso CS, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu AM, Comin-Anduix B, Charych D, Ribas A. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun. 2020 01 31; 11(1):660.
-
Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, Bharadwaj U, Tweardy DJ, Haymaker C, Bernatchez C, Huang S, Rajapakshe K, Coarfa C, Hurwitz ME, Sznol M, Hwu P, Hoch U, Addepalli M, Charych DH, Zalevsky J, Diab A, Overwijk WW. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 01 31; 11(1):661.
-
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, van Schoiack A, Lövgren K, Warren S, Jirström K, Olsson H, Pietras K, Ingvar C, Isaksson K, Schadendorf D, Schmidt H, Bastholt L, Carneiro A, Wargo JA, Svane IM, Jönsson G. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020 01; 577(7791):561-565.
-
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
-
Majd N, Dasgupta P, de Groot J. Immunotherapy for Neuro-Oncology. Adv Exp Med Biol. 2020; 1244:183-203.
-
Tawbi H. A promising start for checkpoint inhibitors in childhood malignancies. Lancet Oncol. 2020 01; 21(1):13-14.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|